Physician profile

Karl B Fields

Family Medicine · Greensboro, NC

NPI 1760437420

$6,388.66

in general payments reported to CMS, 2019-2025

3 companies · $230 in 2025

The $230 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Grant$260.00
Food and Beverage$253.66

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Djo, LLC $6,128.00 2022-2025 Procare
Depuy Synthes Sales INC. $244.68 2019-2025 Monovisc, Orthovisc
Amgen INC. $15.98 2024 Prolia, Evenity

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Karl B Fields

$6,388.66

in general payments reported 2019-2025

Years
2019-2025
Top company
Djo, LLC
Context
The $230 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).

https://glasscript.com/doctor/1181786/karl-b-fields

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.